3,331 16% Admin and others 3,908 4,046 3,850 -1.5% -4.8% 7,759 7,896 1.8% Operating profit 9,676 9,064 9,184 -5.1% 1.3% 19,289 18,247 -5.4% Net foreign exchange gain (loss) -157 -42 -335 113% 688% -380
5,633 7.6% -1.0% 15,875 16,861 6.2% Marketing Expense 1,430 1,840 1,821 27% -1.0% 4,310 5,153 20% Admin and others 3,805 3,850 3,812 0.2% -1.0% 11,565 11,708 1.2% Operating profit 9,501 9,184 8,905 -6.3
แบบ delivery versus payment รวมทั้งก าหนดจุดเวลาที่ให้ถือว่าเป็นที่สุด (finality of settlement) - การให้บริการเป็นศูนย์รับฝากหลักทรัพย์ : มีระบบฝาก ถอน โอนหลักทรัพย์ โดยไม่มี ข้อก าหนดที่เป็นการจ ากัด
international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug
revenues from sales and services from distributor of medical devices and equipment at the 3Q/2017 was 87 million compared to the 2Q/2017. This is because medical devices have been delivery since end of 2Q
of price correction under Clause 4(3) in the newspaper, cheque issuance fees, charges for delivery of price compensation to the relevant purchasers and the person who made redemption of the investment
price, e.g., expenses in placing an announcement of price correction under Clause 4(3) in the newspaper, cheque issuance fees, charges for delivery of price compensation to the relevant purchasers and the
in placing an announcement of price correction under Clause 4(3) in the newspaper, cheque issuance fees, charges for delivery of price compensation to the relevant purchasers and the person who made